- Home
- Publications
- Publication Search
- Publication Details
Title
Targeted Protein Degraders- The druggability perspective
Authors
Keywords
-
Journal
JOURNAL OF PHARMACEUTICAL SCIENCES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-11-04
DOI
10.1016/j.xphs.2023.10.023
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
- (2023) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of Novel Degraders Employing Autophagy for Expediting Medicinal Research
- (2023) Xiang Li et al. Journal of Medicinal Chemistry
- The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
- (2023) Linghui Qian et al. Chemical Reviews
- Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
- (2023) Laurie P. Volak et al. DRUG METABOLISM AND DISPOSITION
- Targeted Protein Degradation: A Promising Option for Cancer Drug Developers
- (2023) Tiffany Yesavage Genetic Engineering & Biotechnology News
- Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation
- (2023) Mengyang Chang et al. Journal of the American Chemical Society
- Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
- (2023) Jing Gao et al. Science Bulletin
- Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
- (2023) Lijie Xing et al. Cancers
- Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy
- (2023) Junjun Fu et al. Cancer Nanotechnology
- Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
- (2023) Barmak Mostofian et al. Journal of Chemical Information and Modeling
- Targeted delivery of PROTAC-based prodrug activated by bond-cleavage bioorthogonal chemistry for microneedle-assisted cancer therapy
- (2023) Jing Huang et al. JOURNAL OF CONTROLLED RELEASE
- Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex
- (2022) Dhanushka Weerakoon et al. Journal of Chemical Information and Modeling
- PROTAC targeted protein degraders: the past is prologue
- (2022) Miklós Békés et al. NATURE REVIEWS DRUG DISCOVERY
- Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
- (2022) Alberto Juan et al. Frontiers in Cell and Developmental Biology
- Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins
- (2022) Josef A. Gramespacher et al. ACS Chemical Biology
- Multifaceted targeted protein degradation systems for different cellular compartments
- (2022) Cornelia E. Zorca et al. BIOESSAYS
- Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches
- (2022) Arvind Negi et al. CHEMBIOCHEM
- Designing Soluble PROTACs: Strategies and Preliminary Guidelines
- (2022) Diego García Jiménez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chaperone-Mediated Autophagy: A Potential Target for Metabolic Diseases
- (2022) Ming Yang et al. CURRENT MEDICINAL CHEMISTRY
- Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs
- (2022) Ioannis Avgeris et al. BIOORGANIC CHEMISTRY
- BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes
- (2022) Li Ma et al. CANCER BIOLOGY & THERAPY
- New steps on an old path: novel estrogen receptor inhibitors in breast cancer
- (2022) Martina Pagliuca et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Recent advances in the development of EGFR degraders: PROTACs and LYTACs
- (2022) Dawei Hong et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Selective PARP1 Inhibitors, PARP1-based Dual-Target Inhibitors, PROTAC PARP1 Degraders, and Prodrugs of PARP1 Inhibitors for Cancer Therapy
- (2022) Xiaopeng Peng et al. PHARMACOLOGICAL RESEARCH
- Targeted Protein Degradation: Clinical Advances in the Field of Oncology
- (2022) Abdelrahman K. A. A. Salama et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The therapeutic prospects of N-acetylgalactosamine-siRNA conjugates
- (2022) Lei Zhang et al. Frontiers in Pharmacology
- Aptamer-Based Probes for Cancer Diagnostics and Treatment
- (2022) Xueqi Hu et al. Life-Basel
- Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
- (2021) Adam D. Cotton et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
- (2021) Yaxian Zhou et al. ACS Central Science
- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
- (2021) Green Ahn et al. Nature Chemical Biology
- From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation
- (2021) Carlotta Cecchini et al. Frontiers in Chemistry
- Ubiquitination, Biotech Startups, and the Future of TRIM Family Proteins: A TRIM-Endous Opportunity
- (2021) Utsa Bhaduri et al. Cells
- 564TiP A phase Ib dose-escalation study of ZN-c5, an oral selective estrogen receptor degrader (SERD), in combination with abemaciclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer
- (2021) G.P. Keogh et al. ANNALS OF ONCOLOGY
- LYTACs: An Emerging Tool for the Degradation of Non‐Cytosolic Proteins
- (2021) Bhavana Ramadas et al. ChemMedChem
- Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery
- (2021) Guoqiang Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Lysosome-targeting chimeras evolve
- (2021) Joshiawa Paulk Nature Chemical Biology
- Small molecule probes for targeting autophagy
- (2021) Thomas Whitmarsh-Everiss et al. Nature Chemical Biology
- Advances in PSMA-targeted therapy for prostate cancer
- (2021) Fujin Wang et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation
- (2021) Hao Cui et al. ACS Omega
- Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL–Specific Degrader DT2216
- (2021) Dinesh Thummuri et al. MOLECULAR CANCER THERAPEUTICS
- Targeting cancer metabolism in the era of precision oncology
- (2021) Zachary E. Stine et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
- (2020) Marı́a Maneiro et al. ACS Chemical Biology
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Targeted protein degradation: current and future challenges
- (2020) Alexander Hanzl et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
- (2020) Yonghan He et al. Journal of Hematology & Oncology
- Receptor-Specific Delivery of Peptide Nucleic Acids Conjugated to Three Sequentially Linked N-Acetyl Galactosamine Moieties into Hepatocytes
- (2020) Pramod Bhingardeve et al. JOURNAL OF ORGANIC CHEMISTRY
- Understanding and Improving the Membrane Permeability of VH032-Based PROTACs
- (2020) Victoria G. Klein et al. ACS Medicinal Chemistry Letters
- Modeling the Degradation Effects of Autophagosome Tethering Compounds
- (2020) Hang Zhang et al. Neuroscience Bulletin
- Solution Conformations Shed Light on PROTAC Cell Permeability
- (2020) Yoseph Atilaw et al. ACS Medicinal Chemistry Letters
- Recent advances in the determination of unbound concentration and plasma protein binding of drugs: Analytical methods
- (2020) Behrouz Seyfinejad et al. TALANTA
- Lipid-Based Nanocarriers for Lymphatic Transportation
- (2019) Nikhar Vishwakarma et al. AAPS PHARMSCITECH
- Targeting IRAK4 for Degradation with PROTACs
- (2019) Joao Nunes et al. ACS Medicinal Chemistry Letters
- A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
- (2019) Shengnan Yu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Development of targeted protein degradation therapeutics
- (2019) Philip P. Chamberlain et al. Nature Chemical Biology
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Development of a PDEδ-Targeting PROTACs that Impair Lipid Metabolism
- (2019) Michael Winzker et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- AUTACs: Cargo-Specific Degraders Using Selective Autophagy
- (2019) Daiki Takahashi et al. MOLECULAR CELL
- Selective degradation of BET proteins with dBET1, a proteolysis-targeting chimera, potently reduces pro-inflammatory responses in lipopolysaccharide-activated microglia
- (2018) Kelly M. DeMars et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
- (2018) Yasuaki Anami et al. Nature Communications
- GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
- (2018) Aaron D. Springer et al. Nucleic Acid Therapeutics
- Squeezing for Life – Properties of Red Blood Cell Deformability
- (2018) Rick Huisjes et al. Frontiers in Physiology
- Unraveling the interaction between carboxylesterase 1c and the antibody-drug conjugate SYD985: improved translational PKPD by using CES1c knockout mice
- (2018) Ruud Ubink et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic targeting HER2 and EGFR with a bivalent aptamer-siRNA chimera efficiently inhibits HER2-positive tumor growth
- (2018) LU XUE et al. MOLECULAR PHARMACEUTICS
- Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility
- (2018) Matthew R. Naylor et al. JOURNAL OF MEDICINAL CHEMISTRY
- Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives
- (2018) Carla Esposito et al. Genes
- Autophagy-regulating protease Atg4: structure, function, regulation and inhibition
- (2017) Tatsuro Maruyama et al. JOURNAL OF ANTIBIOTICS
- Sulphonamide inhibition studies of the β-carbonic anhydrase from the bacterial pathogen Clostridium perfringens
- (2017) Daniela Vullo et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nonclassical Size Dependence of Permeation Defines Bounds for Passive Adsorption of Large Drug Molecules
- (2017) Cameron R. Pye et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia
- (2016) Sujan Piya et al. Autophagy
- Passive Membrane Permeability in Cyclic Peptomer Scaffolds Is Robust to Extensive Variation in Side Chain Functionality and Backbone Geometry
- (2016) Akihiro Furukawa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exploring experimental and computational markers of cyclic peptides: Charting islands of permeability
- (2015) Conan K. Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Differences in Rat and Human Erythrocytes Following Blood Component Manufacturing: The Effect of Additive Solutions
- (2015) Luciana da SilveiraCavalcante et al. TRANSFUSION MEDICINE AND HEMOTHERAPY
- Multifunctional Lactobionic Acid-Modified Dendrimers for Targeted Drug Delivery to Liver Cancer Cells: Investigating the Role Played by PEG Spacer
- (2014) Fanfan Fu et al. ACS Applied Materials & Interfaces
- Exploring the Impact of Drug Properties on the Extent of Intestinal Lymphatic Transport - In Vitro and In Vivo Studies
- (2014) Emma Lawless et al. PHARMACEUTICAL RESEARCH
- Species differences in drug plasma protein binding
- (2014) Nicola Colclough et al. MedChemComm
- Species Difference of Esterase Expression and Hydrolase Activity in Plasma
- (2012) Fatma Goksin Bahar et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Comparative Analysis of Esterase Activities of Human, Mouse, and Rat Blood
- (2011) E. V. Rudakova et al. BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE
- Hepatocyte Targeting and Intracellular Copper Chelation by a Thiol-Containing Glycocyclopeptide
- (2010) Anaïs M. Pujol et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The Genome of the Western Clawed Frog Xenopus tropicalis
- (2010) U. Hellsten et al. SCIENCE
- The role of molecular physicochemical properties and apolipoproteins in association of drugs with triglyceride-rich lipoproteins: in-silico prediction of uptake by chylomicrons
- (2009) Pavel Gershkovich et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- In Vitro and in Vivo Studies on Plasma-to-Blood Ratio of Paclitaxel in Human, Rabbit and Rat Blood Fractions
- (2008) Xiang-Rui Liu et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Physiochemical drug properties associated with in vivo toxicological outcomes
- (2008) Jason D. Hughes et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Generation of a Set of Simple, Interpretable ADMET Rules of Thumb
- (2008) M. Paul Gleeson JOURNAL OF MEDICINAL CHEMISTRY
- Deep Coverage Mouse Red Blood Cell Proteome
- (2008) Erica M. Pasini et al. MOLECULAR & CELLULAR PROTEOMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started